Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paul Mieyal comes back to Nephros

This article was originally published in Clinica

Executive Summary

Paul Mieyal has returned to lead hemodialysis filtration specialist Nephros, filling the role of acting president, acting CEO and acting chief financial officer. Dr Mieyal had been acting CEO of the firm between 2010 and 2012, when he was replaced by John Houghton, from whom Dr Mieyal has now reprised the role. Nephros did not say why Mr Houghton was leaving or if he had another job, nor did the company comment on whether they plan to make Dr Mieyal’s new roles permanent at some point. Dr Mieyal is vice-president and director of life sciences investments at Wexford Capital; and from 2000 to 2006, was vice-president in charge of healthcare investments for Wechsler & Co, a private investment firm and registered broker dealer. In addition, the company has appointed a new chair, Daron Evans; has been a board member since 2013.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT102263

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel